Michael Laffan is Professor of Haemostasis and Thrombosis in the department of haematology.He trained in medicine at the University of Oxford and trained in haematology at the Hammersmith and Royal Free hospitals. His principal research interests are the structure function relationship of von Willebrand factor, in particular the role of glycosylation, and the mechanisms and regulation of thrombin generation. He is director of the Hammersmith Hospital Haemophilia centre and is responsible for postgraduate education in haematology.
Jayakody Arachchillage D, 2022, Autoimmune disease and COVID-19- a multicentre observational study in the United Kingdom, Rheumatology, ISSN:1462-0324
et al., 2022, Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review, Haemophilia, ISSN:1351-8216
et al., 2022, Valoctocogene roxaparvovec gene therapy for hemophilia A., The New England Journal of Medicine, Vol:386, ISSN:0028-4793, Pages:1013-1025
Crossette-Thambiah C, Laffan M, Arachchillage D, 2022, Lupus Anticoagulant and Cardiopulmonary Bypass, WILEY, Pages:43-43, ISSN:0007-1048
Simini G, Akor F, Laffan M, 2022, Subcutaneous unfractionated heparin in patients with end-stage kidney disease requiring anticoagulation, WILEY, Pages:211-212, ISSN:0007-1048